Insight Pharma BD Salon in Nanjing: Deep Dive into Strategic Collaboration and Globalization Pathways
Sanofi
Pharmaceutical Manufacturer
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Everest Medicines
Developer of Innovative Therapies
CHIATAI TIANQING
High-quality pharmaceuticals research, production, and sales provider
Currently, the business development (BD) model in China’s pharmaceutical industry is undergoing a transition from “single-point licensing” to “ecosystem co-creation.” The number of license-out deals has repeatedly hit record highs, while new models such as NewCo structures and joint R&D and investment are rapidly emerging. However, transaction structures are becoming increasingly complex, legal and intellectual property risks are becoming more prominent, and strategic transformation pathways remain unclear. Amid the wave of globalization, companies face unprecedented opportunities yet urgently need practical, in-depth forums for dialogue.
Based on this,Dingxiangyuan Insight, themed “Reconstructing Boundaries · Ecosystem Win-Win,” has organized this salon to focus on key topics such as strategic-level business development (BD) collaboration and exchange, tiered pathways for the global expansion of innovative drugs, and core barriers in cross-border transactions., with a special roadshow session added to provide industry collaborators with an exclusive forum for precise matchmaking, focused discussions, and high-density networking. Numerous renowned pharmaceutical companies, investors, and project developers have already registered. We cordially invite more industry peers to join this salon, engage in face-to-face exchanges with key partners in the pharmaceutical sector, and explore potential collaboration opportunities!
Organizer:Dingxiangyuan Insight Database
Event Duration:Thursday, July 2, 2026, 13:00–17:00
Event Venue:Nanjing Jiangbei New Area Bio-Medicine Valley
Event Scale:50 people
Pre-registration (Review-based)
Scan the QR code to register for free. The conference customer service team will contact you to send the invitation letter.
For conference collaboration, please contact：Manager Hong 15056326013
*Under update; please refer to the latest version.
Call for Companies to Participate in Roadshow
Innovative Pharmaceutical and Biotech Companies with Collaboration Potential Are Welcome to Register for Free Roadshows
Call for Submissions
Pipeline Stage: Priority for Entry into Clinical Stage
Core Assets: Innovative technologies/pipelines with independent intellectual property rights or global equity
Scientific Foundation: Possessing clear scientific logic and a differentiated development strategy
Cooperation Intent: Clear needs for external collaboration, financing, or out-licensing
Application Channel
Contact:Manager Hong 15056326013(Same number for WeChat; please note "Roadshow")
Deadline: June 26, 2026
About DXY Insight
About the DXY Insight Database
Dingxiangyuan Insight Database, a subsidiary of Dingxiangyuan, is China's leading new drug data intelligence platform and data reporting service provider.
As a pioneer in pharmaceutical data, the DXY Insight Database has been dedicated to the pharmaceutical industry for 20 years, serving over 3,000 enterprises. Notably, 92% of RDPAC member companies are long-term partners of Insight. It empowers clients to rapidly grasp the competitive landscape and make precise decisions on new drug development, helping enterprises “make more accurate decisions and work more efficiently.”